Guidance Outlines Eating Disorder Screening for GLP-1 Drugs
An international consensus panel published prescribing recommendations in World Psychiatry for patients with eating disorder histories.
New Clinical Guidance on GLP-1 Drugs and Eating Disorders
An international panel has published clinical recommendations in World Psychiatry addressing the use of glucagon-like peptide-1 (GLP-1) medications in people with eating disorders.
GLP-1 medications treat type 2 diabetes and support weight management by lowering appetite and making people feel full sooner. Early research suggests these medications may reduce binge-eating episodes for certain individuals. Those same appetite-suppressing effects can create complications for individuals with past or active eating disorders.
Development of the Consensus Recommendations
The guidance was developed through a modified Delphi study led by Aaron Keshen and co-authored by Tanya M. Halliday from the University of Utah.
The research team assembled a panel of 45 clinicians, researchers, and individuals with lived experience. The group completed three rounds of structured feedback to reach agreement on safe prescribing practices.
Screening Protocols and Ongoing Patient Monitoring
Clinicians should screen all patients for active or past eating disorders before initiating a GLP-1 medication prescription.
Follow-up appointments should occur regularly throughout treatment to check whether eating disorder symptoms are starting or worsening. The frequency of monitoring visits should reflect the risk level of each patient.
When a person with an eating disorder receives a GLP-1 prescription, the panel recommended providing evidence-based psychotherapy alongside medical treatment. The guidance also advises providing clear educational materials to both patients and clinical teams.
Situations Where Clinicians Advise Avoiding GLP-1 Drugs
The panel advised that clinicians should generally avoid prescribing GLP-1 medications to patients with active eating disorders.
This precaution applies to anorexia nervosa, atypical anorexia nervosa, and bulimia nervosa when a patient severely restricts food or has lost large amounts of weight. Clinicians are urged to exercise caution with patients who have a recorded history of these conditions.
The authors noted that recommendations are not rigid rules. Prescribers should review overall health, nutrition requirements, specific symptoms, and treatment goals for every patient.
Identified Gaps in Clinical Research and Safety Data
The panel stated that published medical literature lacks long-term data on how GLP-1 medications influence eating disorder risks over time.
The authors called for dedicated clinical trials evaluating GLP-1 receptor agonists in people with binge-eating disorder. They also recommended the creation of stronger prescribing safety practices across clinical care settings.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.


Related Articles
Studying Energy Use for Personalized Weight-Loss Treatments
University of Alberta researchers are studying metabolic adaptation in whole-room calorimeters...
Read article MetabolismHyperpolarized MRI Tracks Liver Enzyme Activity in Fatty Liver
A preclinical study in Sensors & Diagnostics demonstrates a specialized MRI method that maps...
Read article MetabolismGut Bacterium Sugar Promotes Visceral Fat Burning in Early Research
A study in Cell Host & Microbe found a sugar molecule from Clostridium immunis increases...
Read article MetabolismTwo Understudied PFAS Linked to Higher Liver Cancer Risk
Blood levels of two newer PFAS compounds doubled liver cancer odds in a USC study, with the...
Read articleWant medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.